Alx Financial Statements From 2010 to 2024

ALXO Stock  USD 11.41  0.22  1.97%   
Alx Oncology financial statements provide useful quarterly and yearly information to potential Alx Oncology Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Alx Oncology financial statements helps investors assess Alx Oncology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Alx Oncology's valuation are summarized below:
Gross Profit
107 K
Market Capitalization
574.2 M
Enterprise Value Revenue
4.3 K
Earnings Share
(3.74)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental signals for Alx Oncology Holdings, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Alx Oncology's prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Alx Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alx main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9.5 M or Depreciation And Amortization of 877.8 K, as well as many exotic indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0881 or Price Book Value Ratio of 3.54. Alx financial statements analysis is a perfect complement when working with Alx Oncology Valuation or Volatility modules.
  
This module can also supplement Alx Oncology's financial leverage analysis and stock options assessment as well as various Alx Oncology Technical models . Check out the analysis of Alx Oncology Correlation against competitors.

Alx Oncology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets254.3 M242.6 M115.4 M
Slightly volatile
Other Current Liabilities27.1 M25.8 MM
Slightly volatile
Total Current Liabilities37.8 M36 M9.7 M
Slightly volatile
Other Liabilities57.9 K61 K252.5 K
Pretty Stable
Property Plant And Equipment Net11.4 M10.8 MM
Slightly volatile
Accounts Payable4.6 M8.6 M2.3 M
Slightly volatile
Cash21.3 M22.4 M80.5 M
Slightly volatile
Non Current Assets Total56.6 M53.9 M11.4 M
Slightly volatile
Cash And Short Term Investments234.8 M182.7 M105.4 M
Slightly volatile
Net Receivables953.7 K1.1 M935.2 K
Pretty Stable
Common Stock Total Equity28.2 K47.1 K15.2 K
Slightly volatile
Common Stock Shares Outstanding34.2 M43 M26.4 M
Slightly volatile
Non Current Liabilities Total17.7 M16.8 M3.9 M
Slightly volatile
Capital Surpluse375.5 M678.2 M185 M
Slightly volatile
Other Current Assets2.9 M4.9 M1.8 M
Slightly volatile
Total Liabilities74.9 M52.8 M43.5 M
Slightly volatile
Property Plant And Equipment Gross12.7 M12.1 M3.2 M
Slightly volatile
Total Current Assets234.8 M188.7 M106.5 M
Slightly volatile
Capital Stock47.5 K50 K41.3 M
Slightly volatile
Net Working Capital218.2 M152.7 M98.3 M
Slightly volatile
Common Stock32.6 K50 K15.6 K
Slightly volatile
Property Plant Equipment4.7 M4.5 M1.6 M
Slightly volatile
Short and Long Term Debt Total9.3 M17.2 M6.2 M
Slightly volatile
Non Currrent Assets Other6.2 M7.6 M2.3 M
Slightly volatile
Long Term DebtM9.6 M6.7 M
Slightly volatile
Long Term Debt Total8.1 M10.8 M6.8 M
Slightly volatile
Non Current Liabilities Other1.9 M1.2 M961.7 K
Slightly volatile
Current Deferred Revenue8.4 M9.5 M10.3 M
Slightly volatile
Deferred Long Term Liabilities7.6 M8.6 M9.4 M
Slightly volatile
Short Term Debt1.2 M1.6 M850.1 K
Slightly volatile

Alx Oncology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative18.6 M28.5 M9.4 M
Slightly volatile
Other Operating Expenses85.4 M170.3 M45.2 M
Slightly volatile
Research Development148.9 M141.8 M39.7 M
Slightly volatile
Cost Of Revenue1.4 M836 K1.8 M
Pretty Stable
Total Operating Expenses177.9 M169.4 M49.8 M
Slightly volatile
Reconciled Depreciation420 K836 K410.6 K
Very volatile
Interest Income11.2 M10.6 M1.8 M
Slightly volatile
Preferred Stock And Other Adjustments4.2 M4.7 M5.1 M
Slightly volatile
Selling And Marketing Expenses668.8 K752.4 K819.3 K
Slightly volatile

Alx Oncology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation27.6 M26.3 M6.7 M
Slightly volatile
Begin Period Cash Flow46.4 M48.8 M74 M
Slightly volatile
Depreciation420 K836 K410.6 K
Very volatile
Capital Expenditures1.6 M1.3 MM
Slightly volatile
Total Cash From Financing Activities73.3 M59.3 M41.5 M
Slightly volatile
End Period Cash Flow21.3 M22.4 M64.9 M
Slightly volatile
Change To Netincome28.8 M27.4 M7.2 M
Slightly volatile
Change Receivables428.8 K482.4 K525.3 K
Slightly volatile
Dividends Paid72.1 M68.6 M13.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.3 K1.2 K636
Slightly volatile
Dividend Yield0.08810.08390.0179
Slightly volatile
Days Of Payables Outstanding3.9 K3.8 K873
Slightly volatile
Ebt Per Ebit1.090.94441.0031
Pretty Stable
Payables Turnover0.09240.097319.6504
Pretty Stable
Cash Per Share6.654.25093.9669
Slightly volatile
Quick Ratio4.855.103611.1676
Slightly volatile
Net Income Per E B T1.11.151.0191
Slightly volatile
Cash Ratio0.590.62249.7651
Pretty Stable
Days Of Sales Outstanding44.5746.91116
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00981.0466
Very volatile
Current Ratio4.985.240410.9861
Pretty Stable
Fixed Asset Turnover21.4820.469.0112
Slightly volatile
Capital Expenditure Coverage Ratio97.21102116
Pretty Stable
Debt Ratio0.04390.04620.3471
Slightly volatile
Price Sales Ratio1.3 K1.2 K636
Slightly volatile
Receivables Turnover4.468.054.5508
Slightly volatile
Asset Turnover0.0030.00310.142
Slightly volatile
Gross Profit Margin0.07250.08150.0887
Slightly volatile
Operating Cycle44.5746.91116
Slightly volatile

Alx Fundamental Market Drivers

Cash And Short Term Investments182.7 M

Alx Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Alx Oncology Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Alx Oncology income statement, its balance sheet, and the statement of cash flows. Alx Oncology investors use historical funamental indicators, such as Alx Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Alx Oncology investors may use each financial statement separately, they are all related. The changes in Alx Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alx Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Alx Oncology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Alx Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue9.5 M8.4 M
Total Revenue 0.00  0.00 
Cost Of Revenue836 K1.4 M
Ebit Per Revenue(42.48)(40.36)

Pair Trading with Alx Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving together with Alx Stock

  0.64MBIO Mustang Bio Report 3rd of April 2024 PairCorr

Moving against Alx Stock

  0.73YS YS Biopharma Report 22nd of April 2024 PairCorr
  0.45MESO Mesoblast TrendingPairCorr
  0.43SNDL SNDL Inc Buyout TrendPairCorr
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:
Check out the analysis of Alx Oncology Correlation against competitors.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Alx Stock analysis

When running Alx Oncology's price analysis, check to measure Alx Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alx Oncology is operating at the current time. Most of Alx Oncology's value examination focuses on studying past and present price action to predict the probability of Alx Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alx Oncology's price. Additionally, you may evaluate how the addition of Alx Oncology to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is Alx Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.74)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.39)
Return On Equity
(0.71)
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.